Publications by authors named "J-F Boivin"
Background: North American and European health agencies recently warned of severe breathing problems associated with gabapentinoids, including in patients with chronic obstructive pulmonary disease (COPD), although supporting evidence is limited.
Objective: To assess whether gabapentinoid use is associated with severe exacerbation in patients with COPD.
Design: Time-conditional propensity score-matched, new-user cohort study.
Article Synopsis
- Nonvalvular atrial fibrillation (NVAF) is linked to a higher risk of dementia, and while oral anticoagulants (OACs) are important for stroke prevention in NVAF, their impact on dementia risk has been unclear due to previous study limitations.
- A research study analyzed data from over 142,000 patients with NVAF to determine if using OACs was associated with a lower incidence of dementia and how the length of OAC use affected this risk.
- The results indicated that OAC use significantly reduced dementia risk (by 12%) among older patients (75+ years), with the most noticeable protective effect seen after around 1.5 years of OAC use, stabilizing afterward, while no
Clinical trials suggest less hepatotoxicity and better adherence with 4 months rifampin (4R) 9 months isoniazid (9H) for treating latent tuberculosis infection (LTBI). Our objectives were to compare frequencies of severe hepatic adverse events and treatment completion, and direct health system costs of LTBI regimens 4R and 9H, in the general population of the province of Quebec, Canada, using provincial health administrative data.Our retrospective cohort included all patients starting rifampin or isoniazid regimens between 2003 and 2007.
View Article and Find Full Text PDFObjective: To assess whether use of antidepressants with strong inhibition of serotonin reuptake is associated with a decreased incidence of ischemic stroke and myocardial infarction (MI).
Methods: We conducted a cohort study using the UK Clinical Practice Research Datalink and considering new users of selective serotonin reuptake inhibitors (SSRIs) or third-generation antidepressants who were ≥18 years of age between 1995 and 2014. Using a nested case-control approach, we matched each case of a first ischemic stroke or MI identified during follow-up with up to 30 controls on age, sex, calendar time, and duration of follow-up.